|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 3.46 Billion
|
|
Market Size (2030)
|
USD 6.21 Billion
|
|
CAGR (2025-2030)
|
10.22%
|
|
Fastest Growing Segment
|
Brain Tumours
|
|
Largest Market
|
North America
|
Market Overview
Global Veterinary Stereotactic Radiosurgery
System Market was valued at USD 3.46 Billion in 2024 and is expected to reach USD
6.21 Billion in the forecast period with a CAGR of 10.22% through 2030. The Global
Veterinary Stereotactic Radiosurgery (VSRS) System Market is expanding rapidly
due to the increasing prevalence of cancer in pets, particularly in dogs and
cats. As more pets are diagnosed with tumors, owners are seeking advanced
treatment options to improve the health outcomes of their animals. Veterinary
stereotactic radiosurgery is a non-invasive and highly effective treatment that
delivers precise doses of radiation to tumors, providing a safer and more
efficient alternative to traditional surgery. This trend is being supported by
the growing awareness among pet owners about the availability of specialized
treatment options, which are driving the demand for these advanced medical
technologies. The continuous development of new and improved radiosurgery
systems that are tailored to animal anatomy is also a significant factor in the
market's growth, making it easier for veterinary clinics to offer these
services.
In addition to the increasing demand for advanced
veterinary treatments, the rising pet ownership across various regions is
playing a pivotal role in market growth. With more households adopting pets,
the demand for veterinary care services is growing, resulting in the expansion
of veterinary clinics and hospitals. As the quality of pet healthcare continues
to improve, more pet owners are opting for advanced treatment options such as
stereotactic radiosurgery. This increase in pet care expenditure and a focus on
providing pets with better quality of life have paved the way for the wider
adoption of stereotactic radiosurgery systems. Innovations in the field of
veterinary oncology, including the development of new techniques and technology
improvements, also support the market's growth, offering more accurate and
personalized treatment plans for pets.
Despite the strong growth trajectory, the market faces
certain challenges that could hinder its expansion. One of the primary
obstacles is the high cost of implementing stereotactic radiosurgery systems,
which can be prohibitive for smaller veterinary practices, particularly in
emerging markets. The initial investment in the equipment, along with the need
for specialized training and qualified professionals to operate the systems,
limits accessibility for some veterinary clinics. Furthermore, while stereotactic
radiosurgery is an effective treatment option, it requires precise technology
and highly skilled veterinarians to ensure successful outcomes. As such, there
is a need for continuous education and professional development to keep up with
the latest advances in the field. Regulatory issues surrounding the approval
and use of new medical technologies can also slow the market’s expansion, as
compliance with local medical device regulations may delay product launches in
various regions. Despite these challenges, the market is expected to continue
its growth, driven by increasing pet healthcare spending, technological
innovations, and an expanding global awareness of veterinary oncology
treatments.
Key Market Drivers
Rising
Pet Ownership
Rising pet ownership globally significantly drives
the growth of the Global Veterinary Stereotactic Radiosurgery System Market. As
more individuals adopt pets, particularly dogs and cats, the demand for
advanced healthcare services for animals has increased substantially. This
trend is especially pronounced in developed countries, where pets are
increasingly viewed as family members. Consequently, owners are seeking
higher-quality, specialized veterinary treatments, including stereotactic
radiosurgery (SRS), which offers a non-invasive, precise approach for treating
tumors in pets. This is particularly important for conditions such as brain and
spinal tumors, where traditional surgical procedures may pose higher risks.
In India, the 21st Livestock Census
is scheduled for 2024, aiming to provide comprehensive data on the livestock
population, including pets. The previous census in 2019 reported a total
population of stray dogs and stray cattle in the country as 20.33 million. This
substantial number highlights the significant presence of animals that may
require veterinary care, including advanced treatments like SRS. As the number
of pets grows, particularly in emerging markets where pet ownership is on the
rise, veterinary clinics are incorporating more advanced technologies,
including SRS, to meet this growing demand.
With pets increasingly considered family members,
their owners are more willing to invest in high-cost, advanced treatments. This
shift in attitudes toward pet healthcare, coupled with the increased
availability of sophisticated veterinary technologies, is expected to propel
the growth of the Global Veterinary Stereotactic Radiosurgery System Market in
the coming years. The rising pet population, combined with a growing
willingness among pet owners to invest in advanced medical treatments, creates
a favorable environment for the adoption of SRS technologies in veterinary
care. This trend is expected to continue as pet ownership grows and pet
healthcare evolves to meet higher standards.
Advancements
in Veterinary Oncology
Advancements in veterinary oncology are significantly
propelling the growth of the Global Veterinary Stereotactic Radiosurgery System
Market. As veterinary oncology evolves, treatments for various cancers in
animals have become more effective and accessible. Stereotactic radiosurgery
(SRS), which precisely targets tumors with minimal damage to surrounding
healthy tissues, is at the forefront of these innovations. The ability of SRS
to treat difficult-to-reach tumors, such as those in the brain or spine, without
the need for traditional invasive surgery has made it an attractive option for
veterinary oncologists. These advancements are particularly important as more
animals, especially pets, are diagnosed with various types of cancer, driving
the demand for specialized treatment options.
Cancer is a leading cause of death among older pets. According
to the American Veterinary Medical Association (AVMA), one in four dogs will be
diagnosed with cancer in their lifetime, and this rate increases to nearly one
in two for dogs over 10 years old. Similarly, cancer accounts for almost half
of the deaths in pets over 10 years of age. These statistics highlight
the critical need for effective cancer treatments in veterinary medicine.
Veterinary oncologists are increasingly adopting
cutting-edge technologies and techniques in response to the rising incidence of
cancer among pets. This shift is supported by improved diagnostic capabilities,
including advanced imaging systems that aid in tumor localization, making SRS a
more viable treatment option. The continuous development of radiosurgery
systems and the integration of artificial intelligence in treatment planning
have further enhanced the precision and effectiveness of these therapies. As a
result, veterinary clinics and hospitals are incorporating these advanced
technologies into their service offerings to provide better outcomes for pets
with cancer.
The growing recognition of cancer as a major health
issue in pets has led to increased investment in veterinary oncology research,
fostering the development of new, non-invasive treatment options. These
advancements in veterinary oncology, particularly in non-invasive therapies
such as SRS, are driving market growth. With improved treatment options
available, pet owners are more willing to invest in advanced cancer treatments,
further propelling the demand for veterinary stereotactic radiosurgery systems.
This trend is expected to continue as pet healthcare evolves to meet higher
standards.
Rising
Incidence of Cancer in Pets
The increasing incidence of cancer in pets is a major
driver of the global veterinary stereotactic radiosurgery (SRS) system market.
As companion animals face a growing risk of cancers such as lymphoma, mast cell
tumors, and osteosarcoma, the demand for advanced and effective treatment
options rises. SRS, a non-invasive therapy that delivers precise radiation
doses directly to tumor sites, offers significant advantages in treating
various cancers in animals. Its accuracy in targeting tumors minimizes damage
to surrounding healthy tissues, reducing side effects and improving recovery
times, making it particularly beneficial for treating tumors near critical
structures or in hard-to-reach locations.
Recent studies highlight the rising incidence of
cancer in pets. In India, research conducted by the Indian Council of
Agricultural Research (ICAR) found that 5.03% of dogs had tumors, with specific
cancer types like mammary tumors in female dogs accounting for 13.33%, and
genital tumors in 33.33% of cases.
Further studies indicated that
female dogs were more prone to cancer, representing 70.72% of the cases, and
tumors in males were mostly found in skin and other tissues. These
statistics underscore the growing burden of cancer among pets and emphasize the
need for effective and precise treatment modalities like SRS.
As awareness of SRS's benefits among veterinary
professionals and pet owners increases, its adoption is accelerating, further
propelling the market. The ability of SRS to deliver high precision radiation
makes it a preferred choice for treating tumors in animals with minimal
invasive procedures. This rise in pet cancer cases and the growing preference
for non-invasive, targeted treatments are expected to continue driving the
global veterinary SRS system market's expansion, offering new opportunities for
veterinary care providers and specialists.
Download Free Sample Report
Key Market Challenges
Limited
Availability of Specialized Veterinary Oncologists
The global veterinary stereotactic radiosurgery system
market faces a significant challenge due to the limited availability of
specialized veterinary oncologists. Stereotactic radiosurgery (SRS) requires
highly trained professionals capable of handling complex equipment and
diagnosing cancer in animals. These systems are intricate and demand expertise
not only in using advanced technology but also in understanding the specifics
of veterinary oncology, which differs significantly from human oncology. The
scarcity of skilled veterinary oncologists limits the effective use of
stereotactic radiosurgery systems in clinical practice, especially in regions
where veterinary oncology is still emerging as a specialized field.
The lack of sufficient training and education programs
for veterinary professionals further exacerbates this issue. While veterinary
schools are increasingly offering specialized courses, the demand for trained
oncologists outpaces the supply, making it difficult for veterinary clinics to
adopt SRS as a standard treatment option. In rural or less developed areas,
where access to specialized care is already limited, the situation is even more
pronounced. The financial constraints of veterinary clinics in these regions
also impact their ability to invest in advanced treatments like stereotactic
radiosurgery systems, which require significant capital and ongoing
maintenance.
The challenge of limited availability of skilled
professionals not only hinders the adoption of these systems but also affects
the overall quality of care animals receive. Without adequate expertise, the
potential benefits of stereotactic radiosurgery such as its precision and
non-invasive nature are diminished, leading to underutilization of the
technology. This shortage of specialized veterinary oncologists is a critical
factor restricting market growth and hindering the broader implementation of
SRS in veterinary practices globally.
Concerns
Over Efficacy and Safety
The global veterinary stereotactic radiosurgery (SRS)
system market faces significant challenges concerning the efficacy and safety
of these advanced treatment modalities. SRS systems, including Gamma Knife,
Linear Accelerators (LINAC), Pencil Beam Scanning Radiotherapy (PBRT), and
CyberKnife, are primarily utilized to treat various cancers in animals. While
these technologies offer non-invasive and precise radiation therapy, concerns
persist regarding their effectiveness across diverse animal populations and the
potential risks associated with their use.
A critical issue is the variability in treatment
outcomes. Factors such as tumor type, animal size, and overall health can
influence the success rates of SRS treatments. This variability necessitates
extensive research and clinical trials to establish standardized protocols and
identify which animals are most likely to benefit from SRS. Without robust
data, veterinarians may face challenges in recommending SRS as a viable
treatment option.
Safety concerns also play a pivotal role. While SRS is
designed to minimize damage to surrounding healthy tissues, there remains a
risk of adverse effects. Potential complications include radiation-induced side
effects, which can vary based on the animal's species, age, and health status.
Ensuring that veterinary professionals are adequately trained to operate SRS
equipment and monitor post-treatment effects is essential to mitigate these
risks.
The high costs associated with acquiring and
maintaining SRS equipment further complicate the situation. Many veterinary
practices, especially in emerging markets, may find it financially challenging
to invest in such advanced technologies. This financial barrier can limit
access to SRS treatments, particularly in regions with limited veterinary
oncology services.
Addressing these challenges requires a concerted
effort from manufacturers, veterinary professionals, and researchers.
Investments in research and development are crucial to enhance the efficacy of
SRS systems and expand their applications. Establishing comprehensive training
programs for veterinary practitioners will ensure that they are equipped to
handle the complexities of SRS treatments safely. Additionally, exploring
financial models or partnerships can make SRS more accessible to a broader
range of veterinary practices, ultimately improving cancer care for animals
worldwide.
Key Market Trends
Growing
Adoption of Non-Invasive Treatments
The increasing preference for non-invasive treatments
in veterinary care is a key trend driving the growth of the Global Veterinary
Stereotactic Radiosurgery System Market. With rising awareness about animal
welfare and advancements in veterinary medicine, pet owners and veterinarians
are increasingly opting for procedures that reduce the physical trauma and
recovery time associated with traditional surgical methods. Stereotactic
radiosurgery (SRS) represents a significant shift in the approach to treating tumors
in pets, offering a non-invasive alternative to conventional surgery. SRS
targets tumors with high precision, delivering radiation with minimal harm to
surrounding healthy tissues, which makes it an appealing choice for treating
brain and spinal tumors, particularly in older or high-risk animals.
The demand for non-invasive treatments is growing as
pets are considered more than just animals; they are seen as beloved family
members. Pet owners are more inclined to invest in medical solutions that
provide less discomfort and faster recovery for their pets. SRS provides these
advantages, allowing animals to recover with minimal pain and short
hospitalization, which is an attractive proposition for both pet owners and
veterinary professionals. The popularity of non-invasive treatments is further
fueled by their success in human medicine, where techniques like radiosurgery
and targeted radiation therapy have seen widespread use for treating tumors in
humans. As these methods become more well-known and accepted, the veterinary
industry has followed suit, recognizing the potential for improved patient
outcomes.
Veterinary clinics are adopting these advanced
technologies to meet the growing demand for high-quality, efficient care. The
rise in pet healthcare investments and the broader trend of minimizing
procedural invasiveness have created a favorable environment for the growth of
the veterinary stereotactic radiosurgery system market. This trend is expected
to continue as veterinary professionals increasingly embrace non-invasive
techniques to enhance treatment precision and improve the overall well-being of
pets.
Growing
Interest from Veterinary Educational Institutions
Veterinary educational institutions are increasingly
adopting advanced technologies, including stereotactic radiosurgery (SRS), to
enhance cancer treatment options for animals. This growing interest is evident
through significant investments in state-of-the-art equipment and specialized
training programs.
For instance, in September 2024,
the LSU School of Veterinary Medicine acquired a Varian Trilogy linear
accelerator. This acquisition enables the institution to offer advanced
stereotactic radiotherapy and intensity-modulated radiation therapy (IMRT) using
RapidArc technology, improving treatment precision and reducing sedation time
for animal patients.
Similarly, the University of Florida's College
of Veterinary Medicine enhanced its cancer treatment capabilities with the
addition of a Varian Edge linear accelerator in October 2021. This
technology allows veterinary oncologists to treat tumors previously deemed
inaccessible, thereby expanding therapeutic options for animal patients.
A 2022 survey highlighted the
growing adoption of advanced radiation therapy in veterinary medicine. The
survey revealed that 59% of respondents had intensity-modulated radiation
therapy (IMRT) capabilities, with 92% of IMRT users also performing stereotactic
radiation therapy (SRT). This indicates a significant trend towards
incorporating sophisticated radiation therapies in veterinary practices.
These developments underscore a broader trend within
veterinary education and practice towards embracing cutting-edge technologies
to improve animal healthcare outcomes. By integrating advanced treatments like
SRS, veterinary institutions aim to provide more effective and less invasive
options for managing cancer in animals, aligning with the evolving expectations
of pet owners and the broader veterinary community.
Segmental Insights
Product
Insights
Based
on the Product, LINAC (Linear Accelerator) systems emerged as the dominant
segment in the Global Veterinary Stereotactic Radiosurgery System Market in
2024. This is due to its advanced capabilities in delivering precise,
high-dose radiation to target tumors in animals. LINAC systems are favored for
their ability to perform non-invasive treatments with minimal damage to
surrounding healthy tissues, making them particularly effective for treating a
variety of cancers in animals, including those located in hard-to-reach areas. LINAC
systems offer flexibility in treatment planning, with the ability to adapt to
different animal sizes and tumor types, making them versatile for use in
veterinary practices. Their high accuracy in delivering radiation ensures that
the therapeutic doses are precisely administered, reducing the risk of side
effects and enhancing treatment efficacy. Furthermore, LINAC technology is
widely recognized in human medicine, which contributes to its adoption in
veterinary oncology centers, as many facilities already use these systems for
human treatments, thus lowering the initial investment barriers.
End
User Insights
Based on the End User, Veterinary
Hospitals emerged as the dominant segment in the Global Veterinary Stereotactic
Radiosurgery System Market in 2024. This growth can be attributed
to the increasing demand for advanced veterinary care and specialized treatment
options for animals. Veterinary hospitals are equipped with the infrastructure,
expertise, and resources necessary to integrate cutting-edge technologies like
SRS systems into their practices, offering highly specialized oncology services
for pets, particularly for complex cases such as cancer. These hospitals
typically house advanced diagnostic and imaging equipment, which is crucial for
the precise planning and execution of SRS treatments. The ability to provide
advanced, non-invasive treatments like stereotactic radiosurgery makes
veterinary hospitals attractive to pet owners seeking the best possible care
for their animals, especially for those with limited treatment options.
Moreover, the growing awareness of cancer treatment in pets, particularly among
affluent pet owners, has led to an increased preference for veterinary
hospitals that offer these sophisticated procedures.
Download Free Sample Report
Regional Insights
North America emerged
as the dominant region in the Global Veterinary Stereotactic Radiosurgery
System Market in 2024. This is driven by several
key factors. The region boasts advanced veterinary healthcare infrastructure,
with a high concentration of well-established veterinary hospitals and
specialized oncology centers that are equipped with state-of-the-art
technologies like SRS systems. North American pet owners are increasingly
seeking sophisticated treatments for their animals, especially for complex and
life-threatening conditions such as cancer. This growing demand for advanced
veterinary care has significantly contributed to the widespread adoption of SRS
technologies. Additionally, the region benefits from robust economic
conditions, allowing veterinary hospitals to invest in high-cost equipment such
as Linear Accelerators (LINAC) and other SRS technologies. The presence of
leading veterinary SRS system manufacturers and research institutions in North
America has further supported the market’s growth, with continuous innovation
in radiation therapy techniques.
Asia-Pacific emerged as
the fastest growing region in the Global Veterinary Stereotactic Radiosurgery
System Market during the forecast period. This is driven by significant advancements in veterinary
healthcare infrastructure and an increasing focus on animal welfare. In many
Asia-Pacific countries, there has been a rising awareness among pet owners
about advanced medical treatments, including for conditions such as cancer,
which has led to higher demand for specialized veterinary care. This heightened
awareness is especially prominent in economically growing nations like China,
Japan, and South Korea, where a shift towards more sophisticated healthcare
options for pets is occurring. As disposable incomes increase and pet ownership
grows, there is a shift towards seeking advanced, non-invasive treatment
options, further boosting the adoption of SRS systems.
Recent Developments
- In September 2024, LSU Vet Med advanced its veterinary
oncology capabilities with the acquisition of a Varian Trilogy linear
accelerator. This cutting-edge equipment allows for the delivery of advanced
stereotactic radiotherapy and intensity-modulated radiation therapy (IMRT) with
RapidArc technology. The system improves the precision of cancer treatments,
minimizes side effects, and significantly reduces sedation time for animal
patients, reflecting the increasing adoption of stereotactic radiosurgery systems
in veterinary care.
- In September 2024, Blue Pearl Veterinary
Hospital in Malvern, Pennsylvania, became one of the first veterinary clinics
worldwide to implement the CyberKnife system, an advanced technology for
treating cancer in animals. The CyberKnife is a unique radiation delivery
system that combines a linear accelerator with a robotic platform, allowing for
the precise administration of high-energy x-rays or photons for radiation
therapy. This breakthrough marks a significant advancement in veterinary
oncology, enabling more targeted and effective cancer treatments.
- In June 2024, Bristol Vet Specialists (BVS) unveiled a
state-of-the-art veterinary hospital with USD 17.44 million investment. The
facility is home to one of England’s few stereotactic linear accelerators for
pets, positioning it as a leader in providing high-precision cancer treatments.
This advanced technology offers faster treatment times, fewer side effects, and
better patient outcomes, underscoring the growing demand for sophisticated stereotactic
radiosurgery systems within the veterinary sector.
- In May 2024, Elekta launched its latest linear
accelerator, Evo*, which incorporates cutting-edge AI-powered high-definition
imaging. This CT-Linac system is capable of supporting both online and offline
adaptive radiation therapy, along with enhanced image-guided radiation
treatments. Its flexibility allows clinicians to tailor the most suitable
radiation therapy method for each individual patient, offering a significant
improvement in the precision and personalization of cancer care.
- In February 2024, Varian Medical Systems, Inc.
received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for
its TrueBeam and Edge radiotherapy systems equipped with the HyperSight imaging
solution. This milestone solidifies the role of cutting-edge radiotherapy
technologies in veterinary oncology, offering veterinary hospitals the tools
needed to treat complex cancers in pets with increased accuracy.
- In October 2023, Thrive Pet Healthcare expanded its
network to over 380 locations across 37 U.S. states with the launch of Thrive
Pet Healthcare Specialists in Hoffman Estates. The facility provides
round-the-clock emergency care for pets with critical conditions and specialty
services by appointment. This expansion highlights the increasing emphasis on
specialized, high-quality veterinary care, with a growing focus on advanced
oncology treatments such as stereotactic radiosurgery to address the rising incidence
of cancer in pets.
Key Market Players
- Avante
Health Solutions
- Accuray
Inc.
- Elekta
AB
- Varian
Medical Systems Inc.
- PetCure
Oncology
- Xstrahl
Inc.
- CVS
Group
- Medtronic
PLC
- Nanovi
AS
- Merck
& Co. Inc.
|
By Product
|
By Application
|
By End User
|
By Region
|
- Gamma Knife
- LINAC
- Proton Beam Radiation Therapy (PBRT)/ Flash-RT
- CyberKnife
|
- Brain Tumours
- Spinal Tumours
- Other Applications
|
- Veterinary Hospitals
- Veterinary Specialty Clinics
- Research and Academic Institutions
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Veterinary
Stereotactic Radiosurgery System Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- Veterinary
Stereotactic Radiosurgery System Market, By Product:
o
Gamma
Knife
o
LINAC
o
Proton
Beam Radiation Therapy (PBRT)/ Flash-RT
o
CyberKnife
- Veterinary
Stereotactic Radiosurgery System Market, By Application:
o
Brain
Tumours
o
Spinal
Tumours
o
Other
Applications
- Veterinary
Stereotactic Radiosurgery System Market, By End User:
o
Veterinary
Hospitals
o
Veterinary
Specialty Clinics
o
Research
and Academic Institutions
- Veterinary
Stereotactic Radiosurgery System Market, By Region:
o
North
America
§
United
States
§
Canada
§
Mexico
o
Europe
§
France
§
United
Kingdom
§
Italy
§
Germany
§
Spain
o
Asia-Pacific
§
China
§
India
§
Japan
§
Australia
§
South
Korea
o
South
America
§
Brazil
§
Argentina
§
Colombia
o
Middle
East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Veterinary Stereotactic
Radiosurgery System Market.
Available Customizations:
Global Veterinary Stereotactic Radiosurgery System Market
report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Global Veterinary Stereotactic Radiosurgery System Market
is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com